

SCIENCE'S COMPASS

it was only after several years of experimentation with market-based approaches that a national market for sulfur dioxide allowances for some coal and oil-burning electrical utilities was implemented.

The commodity exchanged in the sulfur dioxide market—an "allowance"—is a property right created by EPA and allocated to individual firms. Each year, affected utilities are granted a limited number of allowances. Utilities that "overcomply" by reducing their emissions more than required may sell their excess allowances. Those for whom emissions reduction is expensive may purchase allowances from other utilities. In this way utilities themselves, rather than EPA, decide which of them should do the most to meet the ambitious environmental target. Those who bear the greatest burden receive compensation from those who reduce emissions only a little.

The market for sulfur dioxide emissions is constructed by government. In contrast to a natural market, it was necessary for government to design the conditions necessary for the constructed market to function and to determine how much sulfur dioxide would be emitted. In a natural free market, the industry would decide

how much sulfur dioxide would be emitted. To term it a "free market" does not acknowledge the bureaucratic entrepreneurship that went into the design of the market for sulfur dioxide allowances or the effort that will be required to design new markets, such as a global market for carbon dioxide emissions proposed in the Kyoto accords.

Jay Coggins

Vernon W. Ruttan

Department of Applied Economics, College of Agricultural, Food, and Environmental Sciences, University of Minnesota, St. Paul, MN 55108-6040, USA

CORRECTIONS AND CLARIFICATIONS

In table 1 (p. 1921) of the report "Acoel flatworms: Earliest extant bilaterian metazoans, not members of Platyhelminthes" by I. Ruiz-Trillo *et al.* (19 Mar., p. 1919), "*Fasciolopsis buski*," and "*Moliniformis moliniformis*" should have been "*Moniliformis moniliformis*." The second note for table 1 in the same report should have begun, "A total of 18 species of acoels was sequenced...."

In the letter "Whale origins" by Maureen A. O'Leary (*Science's Compass*, 12 Mar., p.

1641), two of the three mammalian orders listed in the second paragraph were spelled incorrectly. The three orders should have been "Primates, Carnivora, and Rodentia."

Equations 6 and 10 (p. 1701) in the Research Article "Mantle values of thermal conductivity and the geotherm from phonon lifetimes" by A. M. Hofmeister (12 Mar., p. 1699) were incorrectly printed. The correct equations appear below.

$$\kappa_{\text{lat}}(P, T) \propto V^{-1/3} \Sigma \omega_i^4 / \Gamma_i$$

Equation 6.


$$\begin{aligned} \kappa(P, T) = & \kappa(298) \left(\frac{298}{T} \right)^a \\ & \times \exp \left[\frac{4qP}{K'_0} - \left(4\gamma_{\text{Th}} + \frac{1}{3} \right) \int_{298}^T \alpha(\theta) d\theta \right] \\ & \times \left(\frac{K_0 + K'_0 P}{K_0} \right)^{\left[\frac{4\gamma_{\text{Th}} + 1/3}{K'_0} - \frac{4qK_0}{(K'_0)^2} \right]} + f(T) \end{aligned}$$

Equation 10.

Primary Human Hematopoietic Cells

- Unprocessed bone marrow
- Bone marrow CD34⁺ cells
- CD34⁺CD38⁻ cells
- Cord blood CD4⁺ T cells
- Dendritic cell precursors
- Bone marrow mononuclear cells
- Bone marrow AC133⁺ cells
- Irradiated stromal cells
- Cord blood CD19⁺ B cells
- Committed erythroid progenitors
- 4-species panel of bone marrow mononuclear cells
- Hematopoietic assays (colony assays, LTC-IC and ELISA)

Flow cytometric analysis of human bone marrow progenitors. CD34⁺ progenitor cell purity is >95%. Quantities of 3 x 10⁵ to 2 x 10⁷ cells are available from single or multiple donors. AC133⁺ progenitors, a subset of the CD34⁺ cell population, are also available.



The 1999 Poietic Technologies catalog is now available. Contact us today and we will send you this 8 page listing of all of our products and assays.

POIETICS™

904 Wind River lane # 102, Gaithersburg, MD 20878
tel: 888-926-9211; fax 301-926-9224
www.poietic.com

BIOXWHITTAKER
A CAMBREX Company

BIOTECH Patent News

Reports on legal and commercial developments in the biotechnology field.

Delivers the information needed to successfully invest in biotechnology.



Twelve monthly issues covering:

- Biotech Patents • Biotech Applications •
- Litigations • Licenses •
- Research Collaborations •

YEARLY SUBSCRIPTION \$145

BIOTECH Patent News

Call or fax 732-549-1356 for a FREE issue
P.O. Box 4482 Metuchen, NJ 08840
<http://biotechpatent.com/biotech>